Wednesday, April 01, 2020 4:21:32 AM
Have people read the full Mori 2000 report - ?not just the summary- it was a trial - if it can be described that way which lasted only 6 weeks !!!!!!! In 2000 -I think the drs on the board - and those with patent law experience Jesse in particular need to read every last detail to see how this report can be attacked for its extreme limitations - In 2000 a six week trial on less than 60 men only - is now being evoked by the judge to demonstrate the patents fail as obvious -come on guys this is bullshit
Can the full and detailed records of that trial be considered in the most minute detail
A trial I believe in Perth Australia but reported in an American journal
I don’t have any medical expertise but this needs a medical and legal forensic onslaught being applied to it
Jessie - tear it to its worthless shreds
Let’s get new evidence into the equation as to just how wrong this judge has been -The link from post 259012 johnking29 allows you to read the summary but by pressing on the links therein you can access a far more detailed account of the trial -But behind that there must be even more records that can be assessed
Let’s fight .... let’s attack ... we have a problem ... let’s work the problem -if you Americans can get Apollo11 back from disaster you can collectively win this damned appeal
Amarin needs all the help it can get .... this appeal can be won
Ask yourselves what would be the impact on the value of this company if this appeal is won ??
Can the full and detailed records of that trial be considered in the most minute detail
A trial I believe in Perth Australia but reported in an American journal
I don’t have any medical expertise but this needs a medical and legal forensic onslaught being applied to it
Jessie - tear it to its worthless shreds
Let’s get new evidence into the equation as to just how wrong this judge has been -The link from post 259012 johnking29 allows you to read the summary but by pressing on the links therein you can access a far more detailed account of the trial -But behind that there must be even more records that can be assessed
Let’s fight .... let’s attack ... we have a problem ... let’s work the problem -if you Americans can get Apollo11 back from disaster you can collectively win this damned appeal
Amarin needs all the help it can get .... this appeal can be won
Ask yourselves what would be the impact on the value of this company if this appeal is won ??
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
